The biotech venture capital (VC) landscape is experiencing a reset, with firms like Flagship Pioneering, Canaan Partners, and F-Prime Capital adapting their strategies. While Flagship Pioneering emphasizes company creation, Canaan Partners focuses on early-stage opportunities with efficient development paths. F-Prime Capital is leaning towards platform technologies offering multiple therapeutic options. These shifts reflect a more […]